1549 related articles for article (PubMed ID: 33212256)
1. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
4. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
[TBL] [Abstract][Full Text] [Related]
5. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
[TBL] [Abstract][Full Text] [Related]
7. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Manabe T; Kambayashi D; Akatsu H; Kudo K
BMC Infect Dis; 2021 May; 21(1):489. PubMed ID: 34044777
[TBL] [Abstract][Full Text] [Related]
8. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
10. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
[TBL] [Abstract][Full Text] [Related]
11. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
Bosaeed M; Alharbi A; Mahmoud E; Alrehily S; Bahlaq M; Gaifer Z; Alturkistani H; Alhagan K; Alshahrani S; Tolbah A; Musattat A; Alanazi M; Jaha R; Sultana K; Alqahtani H; Al Aamer K; Jaser S; Alsaedy A; Ahmad A; Abalkhail M; AlJohani S; Al Jeraisy M; Almaziad S; Albaalharith N; Alabdulkareem K; Alshowair A; Alharbi NK; Alrabiah F; Alshamrani M; Aldibasi O; Alaskar A
Clin Microbiol Infect; 2022 Apr; 28(4):602-608. PubMed ID: 35026375
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial.
Golan Y; Campos JAS; Woolson R; Cilla D; Hanabergh R; Gonzales-Rojas Y; Lopez R; Finberg R; Balboni A
Clin Infect Dis; 2023 Feb; 76(3):e10-e17. PubMed ID: 36065065
[TBL] [Abstract][Full Text] [Related]
14. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Holubar M; Subramanian A; Purington N; Hedlin H; Bunning B; Walter KS; Bonilla H; Boumis A; Chen M; Clinton K; Dewhurst L; Epstein C; Jagannathan P; Kaszynski RH; Panu L; Parsonnet J; Ponder EL; Quintero O; Sefton E; Singh U; Soberanis L; Truong H; Andrews JR; Desai M; Khosla C; Maldonado Y
Clin Infect Dis; 2022 Nov; 75(11):1883-1892. PubMed ID: 35446944
[TBL] [Abstract][Full Text] [Related]
15. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
Alamer A; Alrashed AA; Alfaifi M; Alosaimi B; AlHassar F; Almutairi M; Howaidi J; Almutairi W; Mohzari Y; Sulaiman T; Al-Jedai A; Alajami HN; Alkharji F; Alsaeed A; Alali AH; Baredhwan AA; Abraham I; Almulhim AS
Curr Med Res Opin; 2021 Jul; 37(7):1085-1097. PubMed ID: 33890544
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Hassanipour S; Arab-Zozani M; Amani B; Heidarzad F; Fathalipour M; Martinez-de-Hoyo R
Sci Rep; 2021 May; 11(1):11022. PubMed ID: 34040117
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Medisetty MK; Patel A; Pujari S
Int J Infect Dis; 2021 Apr; 105():722. PubMed ID: 33601033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
